Você procurou por: bronchiolitis (Inglês - Maltês)

bronchitis bronchiolitis
bronkite bronkjolite infestazzjonijiet

asthma, bronchiolitis
a respiratorja4

asthma, bronchiolitis obliterans, lung disorder, hypoxia
ażżma, bronkolite obliterans, disturb fil-pulmun, ipoxja

bronchiolitis (inflammation of small bronchi with breathing difficulties and wheeze in the chest, associated with cough and fever),
bronkjolite (infjammazzjoni tal-bronki żgħar b'diffikultajiet tan-nifs u tħarħir fis-sider assoċjati ma’ sogħla u deni),

rare (may affect up to 1 in 1,000 people): bronchiolitis (difficulty breathing with or without cough); unsteadiness with walking.
rari (jistgħu jaffettwaw sa persuna 1 minn kull 1,000): bronkijolite (diffikultà biex tieħu n-nifs bis-sogħla jew mingħajrha); ma tkunx sod fil-mixi.

concerning the lower respiratory tract infections like bronchitis or bronchiolitis, an aggravation of symptoms (including bronchospasm) has been observed in patients treated with hemangiol due to the bronchoconstrictive effect of propranolol.
fejn jikkonċerna l-infezzjonijiet tal-apparat respiratorju t'isfel bħal bronkite jew bronkjolite, kien osservat aggravament fis-sintomi (inkluż bronkospażmu) f'pazjenti kkurati b' hemangiol minħabba l-effett ta' restrizzjoni tal-bronki bi propranolol.

in clinical trials for proliferating infantile haemangioma, the most frequently reported adverse reactions in infant treated with hemangiol were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhoea, and vomiting.
f'provi kliniċi għal emanġjoma infantili proliferanti, ir-reazzjonijiet avversi tal-mediċina l-aktar irrapportati fi trabi kkurati bil-hemangiol kienu disturbi fl-irqad, infezzjonijiet fl-apparat respiratorju aggravati bħal bronkite u bronkjolite assoċjati ma' sogħla u deni, dijarea, u rimettar.

obliterative bronchiolitis developed in 21.7% of patients in the tacrolimus group compared with 38.0% of patients in the ciclosporin group (p = 0.025).
bronkjolite obliterattiva żviluppat f’ 21.7% tal-pazjenti tal- grupp li ħadu tacrolimus meta mqabbla mat-38.0% tal-pazjenti li kienu fil-grupp ta’ ciclosporin (p = 0.025).